Sugi Predict

Sugi Predict / Compounds / SCHEMBL1967730

SCHEMBL1967730

SCHEMBL1967730

CCOC(=O)COC1CCN(C(=O)OC(C)(C)C)C1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PRMT5 O14744 2/20 0.44
▸ WDR77 Q9BQA1 2/20 0.44
▸ ITGB3 P05106 3/20 0.41
▸ ITGA2B P08514 3/20 0.41
▸ PIK3CD O00329 4/20 0.41
▸ HPGD P15428 2/20 0.41
▸ ALDH1A1 P00352 3/20 0.41
▸ MEN1 O00255 2/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ MAPT P10636 1/20 0.41
▸ TSHR P16473 1/20 0.40
▸ RECQL P46063 2/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ GLA P06280 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ USP30 Q70CQ3 1/20 0.39
▸ EPHX1 P07099 1/20 0.39
▸ GPR119 Q8TDV5 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1975644 1.00 PRMT5 (0.44) PRMT5WDR77ITGB3ITGA2BPIK3CD
SCHEMBL1980890 1.00 PRMT5 (0.44) PRMT5WDR77ITGB3ITGA2BPIK3CD
SCHEMBL21749249 0.92 ALDH1A1 (0.47) PRMT5WDR77PIK3CDHPGDALDH1A1
SCHEMBL31479896 0.92 ALDH1A1 (0.47) PRMT5WDR77PIK3CDHPGDALDH1A1
SCHEMBL20552373 0.92 ALDH1A1 (0.47) PRMT5WDR77PIK3CDHPGDALDH1A1
SCHEMBL6319049 0.92 HPGD (0.46) PRMT5WDR77ITGB3ITGA2BHPGD
SCHEMBL21063465 0.89 PRMT5 (0.47) PRMT5WDR77PIK3CDHPGDALDH1A1
SCHEMBL8366940 0.89 PRMT5 (0.47) PRMT5WDR77PIK3CDHPGDALDH1A1
SCHEMBL20120311 0.89 NR1H2 (0.46) PRMT5WDR77ITGB3ITGA2BPIK3CD
SCHEMBL26893668 0.89 PRMT5 (0.47) PRMT5WDR77PIK3CDHPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260042749-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2026-02-12 — — US disclosed
US-12545659-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2026-02-10 — — US disclosed
US-20240140919-A1 MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 DENALI THERAPEUTICS INC. 2024-05-02 — — US disclosed
CN-112384509-B Furin inhibitors 葛兰素史密斯克莱知识产权发展有限公司 2024-04-30 — — CN disclosed
US-20240059674-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-02-22 — — US disclosed
EP-3790871-B1 FURIN INHIBITORS GLAXOSMITHKLINE IP DEV LTD (GB) 2024-01-24 — — EP disclosed
EP-3790871-B1 FURIN INHIBITORS GLAXOSMITHKLINE IP DEV LTD (GB) 2024-01-24 — — EP disclosed
US-11773078-B2 Furin inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-10-03 — — US disclosed
US-20230303526-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-09-28 — — US disclosed
CN-116669738-A Pyrimidopyridone derivative as SOS1 inhibitor, and preparation method and application thereof 苏州阿尔脉生物科技有限公司 2023-08-29 — — CN disclosed
EP-2233480-B1 Chemical compounds ASTRAZENECA AB (SE) 2013-05-29 — — EP disclosed
EP-2086939-B8 PYRIDINE CARBOXAMIDES AS 11-BETA-HSD1 INHIBITORS ASTRAZENECA AB (SE) 2011-06-22 — — EP disclosed
US-7964618-B2 2-[(3R)-1-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]-3-piperidyl]acetic acid, for example; compounds possess human 11- beta-hydroxysteroid dehydrogenase type1 enzyme (11 beta HSD1) inhibitory activity and accordingly have value in treatment of disease states including metabolic syndrome ASTRAZENECA AB (SE) 2011-06-21 — — US disclosed
EP-2233480-A1 Chemical compounds AstraZeneca AB (SE) 2010-09-29 — — EP disclosed
EP-2086939-B1 PYRIDINE CARBOXAMIDES AS 11-BETA-HSD1 INHIBITORS ASTRAZENECA AB (SE) 2010-07-28 — — EP disclosed
US-20090312372-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2009-12-17 — — US disclosed
US-20090306075-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2009-12-10 — — US disclosed
EP-2086939-A2 PYRIDINE CARBOXAMIDES AS 11-BETA-HSD1 INHIBITORS AstraZeneca AB (SE) 2009-08-12 — — EP disclosed
US-20080269288-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2008-10-30 — — US disclosed
WO-2008053194-A2 PYRIDINE CARBOXAMIDES AS 11-BETA-HSD1 INHIBITORS ASTRAZENECA AB (SE) 2008-05-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12545659-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK4 PRMT5 181/4885WDR77 339/4885ITGB3 3111/4885
US-20090312372-A1 CHEMICAL COMPOUNDS HSD11B1, CYP11B1, CYP4A11 PRMT5 1413/4885WDR77 3076/4885ITGB3 1899/4885
US-20080269288-A1 CHEMICAL COMPOUNDS HSD11B1, CYP11B1, CYP4A11 PRMT5 1413/4885WDR77 3076/4885ITGB3 1899/4885
US-20260042749-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK4 PRMT5 1244/4885WDR77 451/4885ITGB3 1758/4885
US-20090306075-A1 CHEMICAL COMPOUNDS HSD11B1, CYP11B1, CYP4A11 PRMT5 1413/4885WDR77 3076/4885ITGB3 1899/4885
US-11773078-B2 Furin inhibitors FURIN, TGFB1, PCSK7 PRMT5 3045/4885WDR77 840/4885ITGB3 4076/4885
US-20240059674-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 PRMT5 1914/4885WDR77 158/4885ITGB3 3396/4885
US-20230303526-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 PRMT5 1914/4885WDR77 158/4885ITGB3 3396/4885
US-20240140919-A1 MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 EIF2A, EIF4A2, EIF4EBP1 PRMT5 2204/4885WDR77 908/4885ITGB3 3986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.